Centene Stock Undervalued After Clarity Emerges on Post-ACA Subsidy Expiration, UBS Says

MT Newswires Live12-14

Centene (CNC) stock is undervalued, now that the company has laid out building blocks on how to operate if enhanced affordable care act, or ACA, exchange subsidies expire after 2025, UBS said Friday.

Centene expects a 30% drop in ACA exchange enrollment from 2025, creating a $1 earnings per share headwind for 2026, UBS said in the note, which is conservative compared to its peers. However, the brokerage expects the enrollment decline to be offset partially by 15% per-member-per-month, or PMPM, growth.

The firm also expects Medicaid medical loss ratio to improve in 2026 and Medicare to achieve breakeven by 2027.

"We continue to believe Medicaid rates will improve as states are mandated to pay actuarially sound rates," UBS said. "The rate update for 2025 would suggest states are taking notice and further benefits from repricing will annualize into 2026 as well."

The firm upgraded Centene to buy from neutral with a raised price target to $80.

Centene shares were up more than 3% in recent trading.

Price: 60.03, Change: +2.03, Percent Change: +3.50

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment